Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.
¿Cuál es el ratio P/E de Champions Oncology Inc (CSBR)?
El ratio P/E de Champions Oncology Inc es 17.2804
¿Quién es el CEO de Champions Oncology Inc?
Mr. Robert Brainin es el Chief Executive Officer de Champions Oncology Inc, se unió a la empresa desde 2021.
¿Qué tal es el rendimiento del precio de la acción CSBR?
El precio actual de CSBR es de $5.85, ha disminuido un 1.84% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Champions Oncology Inc?
Champions Oncology Inc pertenece a la industria Life Sciences Tools & Services y el sector es Health Care
¿Cuál es la capitalización bursátil de Champions Oncology Inc?
La capitalización bursátil actual de Champions Oncology Inc es $81.2M
¿Es Champions Oncology Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Champions Oncology Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta